Mylotarg: Revisiting its clinical potential post-withdrawal

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 17, Issue , 2015, Pages 179-190

  Zaro, Jennica L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALICHEAMICIN; CD33 ANTIGEN; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; HYDRAZONE DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); CONJUGATION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRODUCT RECALL;

EID: 85081150297     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-3-319-13081-1_10     Document Type: Article

References (40)

1. Amadori S, Suciu S, Stasi R, Salih HR, Selleslag D, Muus P, De Fabritiis P, Venditti A, Ho AD, Lubbert M, Thomas X, Latagliata R, Halkes CJ, Falzetti F, Magro D, Guimaraes JE, Berneman Z, Specchia G, Karrasch M, Fazi P, Vignetti M, Willemze R, de Witte T, Marie JP (2013) Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIME-MA consortium (AML-17). J Clin Oncol 31(35):4424–4430. doi:10.1200/JCO.2013.49.0771
2. Andrews RG, Singer JW, Bernstein ID (1989) Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 169(5):1721–1731
3. Aplenc R, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi SC, Hirsch B, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Ccrp, Davies SM, Byron P, Smith FO (2013) Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk—Results From The Randomized Phase III Children's Oncology Group (COG) Trial, AAML0531. Blood 122(21):355–355
4. Audran R, Drenou B, Wittke F, Gaudin A, Lesimple T, Toujas L (1995) Internalization of human macrophage surface antigens induced by monoclonal antibodies. J Immunol Methods 188(1):147–154
5. Breccia M, Cimino G, Diverio D, Gentilini F, Mandelli F, Lo Coco F (2007) Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute pro-myelocytic leukemia. Haematologica 92(9):1273–1274
6. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490–1496
7. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JA, Hunter A, Gold-stone AH, Wheatley K (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29(4):369–377. doi:10.1200/JCO.2010.31.4310
8. Burnett AK, Kell WJ, Hills RK, Russell NH, Yin J, Hunter A, Culligan D (2006) The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin is feasible and effective. A Pilot Study. In: Blood, ASH Annual Meeting. vol Abstract 1950
9. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, Milligan D (2012) Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30(32):3924–3931. doi:10.1200/JCO.2012.42.2964
10. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 52(24):6761–6767
11. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ et al (1994) A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 83(7):1760–1768
12. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, Vera P, Bologna S, Briere J, Jais JP, Haioun C, Coiffier B, Morschhauser F, Groupe d’etude des lymphomes de la (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118(1):37–43. doi:10.1182/blood-2010-12-327767
13. Cowan AJ, Laszlo GS, Estey EH, Walter RB (2013) Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Frontiers in Bioscience 18:1311–1334
14. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67(4):1048–1053
15. Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS (2011) Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood 117(20):5306–5313. doi:10.1182/blood-2010-09-309229
16. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF (1984) A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leukemia Res 8(4):521–534
17. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, Bernstein I (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjugate Chem 13(1):40–46
18. Janeway C, Travers P, Walport M, Shlomchik M (2001) Immunobiology. The immune system in health and disease. Garland Science, New York
19. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, Keating M, Freireich E, Albitar M (2002) Differences in CD33 intensity between various my-eloid neoplasms. Am J Clin Pathol 118(4):560–566. doi:10.1309/1WMW-CMXX-4WN4-T55U
20. Kirby T (2012) Louisa Degenhardt: hooked on addiction research. Lancet 379(9810):21. doi:10.1016/S0140-6736(12)60010–5
21. Linenberger ML (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19(2):176–182. doi:10.1038/sj.leu.2403598
22. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Venditti A, Tafuri A, Mandelli F (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 104(7):1995–1999. doi:10.1182/blood-2004-04-1550
23. Lowenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Dohner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J, Dutch-Belgian Hemato-Oncology Cooperative G, German Austrian AMLSG, Swiss Group for Clinical Cancer Research Collaborative G (2010) Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 115(13):2586–2591. doi:10.1182/blood-2009-10-246470
24. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S, Ohno R (2000) Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA –676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14(8):1436–1443
25. Paul SP, Taylor LS, Stansbury EK, McVicar DW (2000) Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96(2):483–490
26. Peiper SC, Ashmun RA, Look AT (1988) Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood 72(1):314–321
27. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121(24):4854–4860. doi:10.1182/blood-2013-01-466706
28. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID (1996) Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56(9):2123–2129
29. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504–510. doi:10.1200/JCO.2008.18.6130
30. Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Dulery R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C (2014) Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. Oncotarget 5(4):916–932
31. Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogami-cin and inotuzumab ozogamicin. Clin Cancer Res 17(20):6417–6427. doi:10.1158/1078-0432. CCR-11-0486
32. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM et al (1992) Human bone marrow depleted of CD33-posi-tive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 79(9):2229–2236
33. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD (1989) Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 3(6):440–445
34. Sievers EL (2003) Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood cells Mol Dis 31(1):7–10
35. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93(11):3678–3684
36. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR, Mylotarg Study G (2001) Efficacy and safety of gemtuzumab ozo-gamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19(13):3244–3254
37. Tanimoto T, Tsubokura M, Mori J, Pietrek M, Ono S, Kami M (2013) Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin. Investigational New Drugs 31(2):473–478. doi:10.1007/s10637-012-9877-8
38. van der Jagt RH, Badger CC, Appelbaum FR, Press OW, Matthews DC, Eary JF, Krohn KA, Bernstein ID (1992) Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res 52(1):89–94
39. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97(10):3197–3204
40. Walter RB, Appelbaum FR, Estey EH, Bernstein ID (2012) Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119(26):6198–6208. doi:10.1182/blood-2011-11-325050